Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism

European Urology

Volumn 61, Issue 6, 2012, Pages 1119-1128

  Hu, Jim C ^a   Williams, Stephen B ^b   O'Malley, A James ^c   Smith, Matthew R ^d   Nguyen, Paul L ^b   Keating, Nancy L ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Hormonal adverse effect; Peripheral vascular disease; Prostatic neoplasms drug therapy; Venous thromboembolism

Indexed keywords

ABARELIX;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CARDIOVASCULAR RISK; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; ORCHIECTOMY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROSTATE CANCER; SMOKING; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; GONADOTROPIN-RELEASING HORMONE; HUMANS; INCIDENCE; MALE; NEOPLASMS, HORMONE-DEPENDENT; ORCHIECTOMY; PATIENT SELECTION; PERIPHERAL ARTERIAL DISEASE; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; SEER PROGRAM; TIME FACTORS; UNITED STATES; VENOUS THROMBOEMBOLISM;

EID: 84862777685     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2012.01.045     Document Type: Article

References (29)

1. N. Mottet, J. Bellmunt, and M. Bolla EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer Eur Urol 59 2011 572 583
2. V. Pagliarulo, S. Bracarda, and M.A. Eisenberger Contemporary role of androgen deprivation therapy for prostate cancer Eur Urol 61 2012 11 25
3. S. Li, X. Li, J. Li, X. Deng, Y. Li, and Y. Cong Experimental arterial thrombosis regulated by androgen and its receptor via modulation of platelet activation Thromb Res 121 2007 127 134 (Pubitemid 350026003)
4. N.L. Keating, A.J. O'Malley, and M.R. Smith Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer J Clin Oncol 24 2006 4448 4456 (Pubitemid 46630983)
5. N.L. Keating, A.J. O'Malley, S.J. Freedland, and M.R. Smith Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer J Natl Cancer Inst 102 2010 39 46
6. C.S. Saigal, J.L. Gore, T.L. Krupski, J. Hanley, M. Schonlau, and M.S. Litwin Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer Cancer 110 2007 1493 1500 (Pubitemid 47463063)
7. A.V. D'Amico, J.W. Denham, and J. Crook Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions J Clin Oncol 25 2007 2420 2425 (Pubitemid 46999213)
8. Van Hemelrijck M, Garmo H, Holmberg L, et al. Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe Sweden. J Clin Oncol;28:3448-56.
9. L. Azoulay, H. Yin, S. Benayoun, C. Renoux, J.-F. Boivin, and S. Suissa Androgen-deprivation therapy and the risk of stroke in patients with prostate cancer Eur Urol 60 2011 1244 1250
10. M. Van Hemelrijck, J. Adolfsson, and H. Garmo Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe Sweden Lancet Oncol 11 2010 450 458
11. M. Bolla, T.M. de Reijke, and G. Van Tienhoven Duration of androgen suppression in the treatment of prostate cancer N Engl J Med 360 2009 2516 2527
12. A.L. Potosky, G.F. Riley, J.D. Lubitz, R.M. Mentnech, and L.G. Kessler Potential for cancer related health services research using a linked Medicare-tumor registry database Med Care 31 1993 732 748
13. J. Margolis, J.J. Barron, and W.D. Grochulski Health care resources and costs for treating peripheral artery disease in a managed care population: results from analysis of administrative claims data J Manag Care Pharm 11 2005 727 734
14. D.L. Hershman, D.L. Buono, J. Malin, R. McBride, W.Y. Tsai, and A.I. Neugut Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer J Natl Cancer Inst 101 2009 1633 1641
15. J.A. Heit, M.D. Silverstein, D.N. Mohr, T.M. Petterson, W.M. O'Fallon, and L.J. Melton III Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study Arch Intern Med 160 2000 809 815 (Pubitemid 30165241)
16. C.N. Klabunde, A.L. Potosky, J.M. Legler, and J.L. Warren Development of a comorbidity index using physician claims data J Clin Epidemiol 53 2000 1258 1267 (Pubitemid 32007842)
17. R.P. Rosenbaum The consequences of adjustment for a concomitant variable that has been affected by the treatment 1984 ROYAUME-UNI, Royal Statistical Society London
18. D.Y. Lin, B.M. Psaty, and R.A. Kronmal Assessing the sensitivity of regression results to unmeasured confounders in observational studies Biometrics 54 1998 948 963 (Pubitemid 28429289)
19. T.J. Vanderweele, and O.A. Arah Bias formulas for sensitivity analysis of unmeasured confounding for general outcomes, treatments, and confounders Epidemiology 22 2011 42 52
20. E. Selvin, and T.P. Erlinger Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000 Circulation 110 2004 738 743 (Pubitemid 39056275)
21. A.G. Holst, G. Jensen, and E. Prescott Risk factors for venous thromboembolism: results from the Copenhagen City Heart Study Circulation 121 2010 1896 1903
22. Smoking and tobacco use. Adult cigarette smoking in the United States: current estimate. U.S. Centers for Disease Control and Prevention Web site. http://www.cdc.gov/tobacco/data-statistics/fact-sheets/adult-data/cig-smoking/ index.htm. Accessed November 18, 2011.
23. M.R. Smith, J.S. Finkelstein, and F.J. McGovern Changes in body composition during androgen deprivation therapy for prostate cancer J Clin Endocrinol Metab 87 2002 599 603 (Pubitemid 34158224)
24. M.R. Smith, H. Lee, and D.M. Nathan Insulin sensitivity during combined androgen blockade for prostate cancer J Clin Endocrinol Metab 91 2006 1305 1308
25. J.C. Smith, S. Bennett, and L.M. Evans The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer J Clin Endocrinol Metab 86 2001 4261 4267 (Pubitemid 32848544)
26. F. Dockery, C.J. Bulpitt, S. Agarwal, M. Donaldson, and C. Rajkumar Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia Clin Sci (Lond) 104 2003 195 201 (Pubitemid 36238052)
27. Ehdaie B, Atoria C, Gupta A, et al. Androgen deprivation and thromboembolic events in men with prostate cancer. Cancer. In press. DOI:10.1002/cncr.26623.
28. A. Heidenreich, D. Pfister, C.H. Ohlmann, and U.H. Engelmann Androgen deprivation for advanced prostate cancer [in German] Urologe A 47 2008 270 283
29. U.H. Winkler Effects of androgens on haemostasis Maturitas 24 1996 147 155